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Objective: Urinary incontinence (UI) is one of the most common urinary system diseases that mostly affects women
but also men.We evaluated the therapeutic efficacy of functional magnetic stimulation (FMS) as potential UI treatment
with improvements in the pelvic floor musculature, urodynamic tests and quality of life.
Methods: A total of 20 UI patients (10 females and 10 men, mean age 64, 14 years), including 10 with stress UI,
four with urgency UI and six with mixed UI, were treated with FMS (20min/session) twice a week for 3weeks.
The patients’ impressions, records in urinary diaries, and scores of three life stress questionnaires (overactive bladder
symptom questionnaire [OAB-q], urogenital distress inventory questionnaire-short form [UDI-6], incontinence impact
questionnaire-short form [IIQ-7]) were performed pre- and post-treatment.
Results: Significant reductions (P<0.01) of micturition number and nocturia after magnetic treatment were evi-
denced. The urodynamic tests recorded a significant increase in cystometric capacity (147±51.3%), in maximum
urethral closure pressure (110±34%), in urethral functional length (99.8±51.8%), and in pressure transmission
ratio (147±51.3%) values compared with the baseline values.
Conclusions: These preliminary findings suggest that FMS with Magneto STYM (twice weekly for 3weeks) improves
the UI and may be an effective treatment for this urogenital disease.
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1. INTRODUCTION
Urinary incontinence (UI) is a common urogenital dis-
ease, defined as the involuntary leakage of urine in the
absence of a detrusor contraction, usually due to the
weakness of the urethral sphincter and pelvic floor.1
The main symptoms are: reduced ‘‘warning time’’ of the
need to void with consequently increased frequency and
reduced volume voided per micturition, with the poten-
tial to result in nocturia.2 According to the International
Continence Society (ICS), the UI affects more than 200
million people worldwide, and mainly women (55%)
rather than men.3 This number may be an underesti-
mate, because up to half of women may fail to report UI
probably due to embarrassment, lack of knowledge about
treatment options, or a conviction that UI is a normal
inevitable part of aging.4
This pathological condition has a negative impact on
the quality of life of patients and can also affect men and
is primarily caused by urethral sphincteric deficiency after
radical prostatectomy.5
UI can be categorized in: (i) urethral underactivity
(stress UI) that accounted from 29 to 75% of the
women;6,7 (ii) bladder overactivity (urgency UI), that
accounted for 7–33% of the total population (22% of
women vs 2.6% of men);8–11 (iii) a combination of the
two previous types (mixed UI), that accounted from 14
to 61% of the population.2,12
The management of UI includes restoration of con-
tinence, reduction of the number of UI episodes, and
prevention of complications (e.g. pressure ulcers).
New and emerging therapies aim to improve the overall
efficacy compared with existing therapies (behavioral,
pharmacological, surgical therapies), while minimizing
adverse effects/complications, improving tolerability, and
reducing invasiveness (Table 1).
Several clinical studies have focused on developing
novel, non-invasive techniques to treat the UI, includ-
ing magnetic stimulation and there have been reported
improvements of the urinary symptoms (e.g. reduction
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TABLE 1. Treatment types of UI
Behavioral therapy Pharmacologic therapy Physical therapy Surgical therapy
Stress UI Pelvic floor muscle training (PFMT) Injectable bulking agents Mid-urethral slings, autologous
pubovaginal slings, retropubic
suspensions (for women); sling,
artificial urethral sphincter (for
men)
Urge UI Lifestyle modifications, timed
voiding, bladder retraining
Antimuscarinics agents;
Beta-3 agonists
Posterior tibial nerve
stimulation (PTNS); sacral
neuromodulation
Mixed UI PFMT Alpha blockers; 5-alpha
reductase inhibitors (for men)
Sacral neuromodulation Bladder outlet procedures (e.g.
transurethral resection of
prostate)
in frequency of leakage, urodynamic improvement, max-
imum bladder capacity) with no side-effects.13–20
There are several types of magnetic stimulation, includ-
ing extracorporeal magnetic stimulation (ExMS) mainly
used for urgency UI, functional magnetic stimulation
(FMS) for stress and mixed UI. The action mechanism
is the same for both types: the magnetic therapy stim-
ulates both central and peripheral nerve pathways in
the pelvis;21and induces a flow of ions, at the tissue
level, establishing electrical eddy currents that can lead
to membrane depolarization, consequently causing the
pelvic floor muscles to contract and reducing UI.22
The aim of this study has been to investigate the
effectiveness of FMS as potential UI treatment with
improvements in the pelvic floor musculature, urody-
namic tests and quality of life of patients who consulted
our ‘‘Second Opinion Medical Network’’ (Modena, Italy)
for the evaluation of their urinary symptoms.
The ‘‘Second Opinion Medical Network’’ is a consul-
tation referral web and Medical Office System recruiting
each time a wide panel of real time available special-
ists, to whom any patient affected by different diseases
not adequately satisfied in terms of diagnosis and treat-
ment can apply for an individual clinical audit.23 Most
of the patients, in fact, often wander around the web
jumping into the medical Web-sites, looking for proper
answers to their health problems, but this screening
becomes often obsessive and compulsive, and frequently
misleading, ending into the ‘‘Web Babel Syndrome (a
doctor-patient communication gap that especially deal-
ing with multiple synchronous pathologies, copes with
heterogeneous and misleading information/advice, with
the impending risk of confused, contradictory statements
and prescriptions).24,25 To face this problem, the ‘‘Sec-
ond Opinion Network’’ aims to be a useful problem-
solving support revisiting each diagnostic and therapeutic
step and properly re-addressing tailored treatments and
prognosis, but also to avoid un-necessary investigational
procedures, undue unhelpful and expensive medical and
surgical treatments.26
2. METHODS
The anecdotic an retrospective observational study
enrolled 20 patients (10 males and 10 females, age
TABLE 2. Clinical characteristics of patients
Number patients 20
Mean age (years) 64.14
Menopause 6
SUI 10
Urgency UI 4
Mixed UI 6
Mean duration of symptoms (years) 2.9
Fig. 1 Patient (women, 66 aa) with Urge Urinary Incontinence in
treatment (first session) with Functional Magnetic Stimulator-Magneto
STYM. [Colour figure can be viewed at wileyonlinelibrary.com].
38–82 years) who visited the ‘‘Second Opinion Medical
Network’’ (Modena, Italy) as new patients for their UI:
10 patients (50%) with stress UI, 4 (20%) with urgency
UI, 6 (30%) with mixed UI (Table 2).
The specific inclusion criteria are: (i) clinical urinary
signs reported by participant and confirmed further by its
medical record; (ii) UI history of at least 6months, (iii) no
history of surgery or hormone replacement therapy for
UI treatment. All the patients provided written informed
consent before participation and detailed personal his-
tory, age, previous diseases, urinary diary (number of
leaks per day, frequency of micturition, nocturia), phys-
ical examination, urinalysis and urodynamic evaluation,
including cystometric capacity (intravesical volume at
which the patient has a normal, strong desire to void),
maximum urethral closure pressure -MUCP- (pressure in
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the urethra keeping the urethra closed over the baseline
bladder pressure), functional urethral length (length of
the urethra over which the urethral pressure exceeds
baseline bladder pressure), pressure transmission ratio-
PTR- (ratio between urethral pressure spikes and bladder
pressure spikes); in order to define the UI type. The study
excluded the patients wearing a cardiac pacemaker or
other implanted metallic pacemaker, or implanted metal-
lic instrument such as urethral stent, and women who
were pregnant or suspected of being pregnant.
The device used was a functional magnetic stimula-
tor -Magneto STYM- (Iskra Medical [Stegne 23, 1000
Ljubljana, Slovenia]) including the magnetic coil that was
positioned beneath the sitting bottom of the chair. During
the treatment, each patient was instructed to sit on the
seat so that the perineum was positioned at the centre
of the coil and so that the patient would feel the muscle
contraction (contraction of the pelvic floor and sphincter
muscles) during stimulation (Fig. 1).
The patients underwent 20min/session, twice a week
for 3weeks (six sessions total).
Stimulation intensity (max 2 Tesla) was gradually
increased, by the clinician, up to the limit of tolerability
as indicated by the patient (average 15–30% of the max-
imum). While stimulation frequency was fixed at 10Hz
for 10min, and at 35Hz for another 10min, with a rest
period (active time and pause time) of 6 sec, respectively.
The control unit displayed the status, the pulse genera-
tion and the possibility for external communication via a
modem.
The efficacy of the FMS was evaluated by the patients’
impressions, records in urinary diaries, urodynamic tests
(performed in the same manner before and after treat-
ment) and scores of three life stress questionnaires admin-
istered pre and post-treatment: (i) Overactive bladder
symptom questionnaire (OAB-q): comprises 33 items
divided into coping, concern, sleep, social interaction,
and total health-related quality of life subscales, during
the past week, and it is scored on a five-point scale (0
for ‘‘not at all’’, 1 for ‘‘a little bit’’, 2 for ‘‘some what’’, 3
for ‘‘quite a bit’’, 4 for ‘‘a great deal’’, 5 for ‘‘a very great
deal’’);27 (ii) Urogenital distress inventory questionnaire-
short form (UDI-6): comprises seven questions on urine
leakage and urgency symptoms over the last 3months,
with a scale of 0–3 (0 for ‘‘not at all’’, 1 for ‘‘slightly’’, 2
for ‘‘moderately’’, and 3 for ‘‘greatly’’);28and (iii) Inconti-
nence impact questionnaire-short form (IIQ-7): comprises
seven questions to assess the adverse effects of UI in terms
of physical activities, household chores, recreation, trav-
elling, social activities, emotional health and the feeling
of frustration. The average, which ranges from 0 to 3 (0
for ‘‘not at all’’, 1 for ‘‘slightly’’, 2 for ‘‘moderately’’, and
3 for ‘‘greatly’’) is multiplied by 33×1/3 to put scores on
a scale of 0–100.29
The statistical analysis was evaluated using
Mann–Whitney test (continuous variables not nor-
mally distributed) and χ2 test (categorical variables).
A commonly-used measure of linear correlation, the
Pearson correlation coefficient, denoted by r, was
reported. Statistical significance was set at P-value less
than 0.05, and all data and graphics were analyzed using
the R software, version 3.1.2.30
3. RESULTS
The mean age of the patients was 64.14±13.61 years.
The changes in UI status were evaluated by comparing
urodynamic tests and life stress scores before FMS and at
3weeks after treatment (Tables 2–4).The patients noticed
significant reductions of micturition number and nocturia
after FMS (P<0.01).
The urodynamic tests recorded a significant
increase in cystometric capacity (147± 51.3%), in
MUCP (110±34%), in urethral functional length
(99.8±51.8%), and in PTR (147± 51.3%) values
compared with the baseline values (Fig. 2).
The urodynamic testing values that decreased with
bladder filling or when the UI patients assuming an
upright posture, were increased after 3weeks of treat-
ment: maximum urethral closure pressure increased in
all the stress UI patients, bladder capacity at first desire
to void and maximum cystometric capacity significantly
increased in four urgency UI patients after stimulation
(P< 0.01).
4. DISCUSSION
Several studies have evidenced that FMS affects UI
through the large fiber somatic nerve and afferent neural
pathway: it induces a magnetic current in the auto-
nomic and somatic nervous systems, innervating the
lower urinary tract in a manner similar to that of elec-
trical stimulation, and improves bladder hyperreflexia
by desensitizing C-afferent fibers and reducing c-fos gene
expression.31 Indeed, Yamanishi and co-workers stud-
ied the urodynamic effects of FMS on urethral closure
in healthy volunteers and concluded that this technique
significantly increased the maximum intraurethral and
urethral closure pressure after stimulation: pulsed elec-
tromagnetic fields (PEMFs) generated by a coil penetrate
deep into the pelvic floor, to reach the relevant conductive
tissues, and induce a flow of ions to propagate electromag-
netic currents.16 Voltage gradient ensues, and membrane
depolarization occurs in the pelvic floor that leads to
pelvic floor nerve stimulation (stimulation of motor end
plates) and to pelvic floor muscle contraction.32 Further,
Galloway et al.13 developed a pulsed magnetic device for
pelvic floor muscle strengthening in the UI treatment
and confirmed a significant reduction in the frequency of
leakage episodes and detrusor instability.
Several reports confirmed also the long-term post-
treatment duration of therapeutic effect.17,33 For instance,
Yokoyama and co-workers reported that 17/20 patients
with urgency UI reduced their urinary symptoms with
FMS, and that 9 of 17 patients (53%) maintained
improvements until 24weeks after the last treatment.17
In the present study, all of the patients who did not need
to undress for the treatment underwent a six-session FMS
protocol, showing a significant improvement in symptom
scales compared with the baseline values and this effect
© 2017 John Wiley & Sons Australia, Ltd
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TABLE 3. Urodynamic testing results (median values) pre and post-treatment
Urodynamic exams Pre-treatment Post-treatment P-value
Cystometric capacity (normal values 300–600mL) 200 (IQR [145.75–239.25]) 419 (IQR [383–429]) <0.01
Maximum urethral closure pressure (MUCP) (normal values ≥30 cm H2O) 21 (IQR [16.75–22.25]) 41 (IQR [38.75–42.25]) <0.01
Urethral functional length (normal values 3.5–5.25 cm) 2.25 (IQR [1.9–2.5]) 4.4 (IQR [3.68–4.93]) <0.01
Pressure transmission ratio (PTR) (normal values ≥100%) 48 (IQR [40–56]) 118 (IQR [109–125]) <0.01
Fig. 2 Graphic illustration of Urodynamic testing results (median values and P-value), including cystometric capacity, maximum urethral closure
pressure (MUCP), urethral functional length, and pressure transmission rate (PTR), of all the patients pre-and post-functional magnetic treatment.
[Colour figure can be viewed at wileyonlinelibrary.com].
TABLE 4. Life stress questionnaires scores (median values) pre and
post-treatment
Questionnaire
type
Baseline
(pre-treatment)
3weeks
(post-treatment) P-value
OAB-q 4 (IQR [3–4.25]) 1 (IQR [0.75–2]) <0.01
UDI-6 3 (IQR [2–3]) 0 (IQR [0–0.25]) <0.01
IIQ-7 22 (IQR [22–33]) 5.5 (IQR [0–11]) <0.01
persisted until the follow-up visit at week 6. However, the
therapeutic effect could be maintained for a considerably
long time after discontinuation of treatment, as confirmed
by the follow-up questionnaire (by post) which revealed
that urodynamic improvement and maximum bladder
capacity was maintained in all of the patients without
any additional pharmacological therapy. This may show a
‘‘re-education effect’’ of FMS, as showed by Suzuki
et al.,33 but it could be necessary to perform a longer
follow-up study in a greater number of patients in order
to verify the therapeutic efficacy of FMS, including
the duration of its re-education effect. Regarding the
safety of the treatment, no adverse effects due to FMS
were noted in this study, as confirmed by Yamanishi
and co-workers in the recent multicenter, randomized,
sham-controlled study; they did record severe adverse
events and observed that the number of leaks/week in
bladder diary, as well as the voided volume and in the
number of urgency/24h, were all significantly reduced
in 101 women with urgency UI.34
However, these data confirm the safety, non-
invasiveness and painlessness of FMS compared to
electrical stimulation which has side-effects, such as
abdominal cramp, diarrhea, pain, and bleeding.35
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5. CONCLUSION
Our preliminary study suggests that FMS with Mag-
netoSTYM (twice weekly for 3 weeks) has significant
advantages (no reported adverse effects, unnecessary to
undress, automatic contractions and no pain), improves
the UI and may be an effective treatment for this urogen-
ital disease.
Nevertheless, further investigation of the optimal
stimulation parameters, and standardization protocol is
required to optimize therapeutic treatment.
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